Chicken IBH (inclusion body hepatitis) egg yolk antibody and application of chicken IBH egg yolk in preparation of chicken IBH treatment drug

A yolk antibody and inclusion body technology, applied in the direction of antibodies, antiviral agents, antiviral immunoglobulins, etc., can solve the problem of low immune efficacy, achieve high antibody titers, good antibody titers, and improve the effect of prevention and treatment.

Inactive Publication Date: 2017-01-11
TIANJIN RINGPU BIO TECH
View PDF2 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] The present invention aims at the technical defects of the prior art, and provides a chicken inclusion body hepatitis egg yolk antibody to solve th

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0042] A chicken inclusion body hepatitis yolk antibody prepared by the following method:

[0043] 1. Preparation of aqueous phase

[0044]Dilute the AV208, AV209 and AV211 virus solutions 10 times with sterilized normal saline respectively, take 10 pieces of 7-day-old SPF chicken embryos, and inoculate 0.2ml (10 4.0 ELD 50 ), hatched for 7 days, discarded the chicken embryos that died before 24 hours, and took out the chicken embryos that died at 48 to 120 hours at any time, and harvested the allantoic fluid. The allantoic fluid of the three virus strains was concentrated 10 times respectively, and then inactivated by adding formaldehyde. The ratio of the three strains is 1:1:1, and the water phase is prepared.

[0045] 2. Vaccine preparation

[0046] After autoclaving Baiyou No. 10, the emulsification ratio of the water phase and the oil phase is 1:1 (V / V), add 0.005% of thimerosal in the final concentration, first introduce the oil phase into the colloid mill, stir at 2...

Embodiment 2

[0058] Example 2 (the yolk antibody prepared in Example 1 is used for the curative effect experiment of treating inclusion body hepatitis)

[0059] 1,000 25-day-old broilers had inclusion body hepatitis outbreaks (with Newcastle disease and Escherichia coli mixed infection), and chicken inclusion body hepatitis egg yolk antibody was injected into the pectoral muscle, 2ml / bird. The epidemic has been effectively controlled, and the cure rate has reached 93%, and no secondary diseases such as colibacillosis have occurred until the slaughter.

Embodiment 3

[0060] Example 3 (the yolk antibody prepared in Example 1 is used for the curative effect experiment of preventing inclusion body hepatitis)

[0061] In the chicken farm where inclusion body hepatitis occurred, 2 groups of chickens (a total of 2000, 20 days old) were selected for emergency prevention, and 2ml / bird was injected into the pectoralis muscle. After the epidemic situation in the chicken farm was brought under control, no inclusion body hepatitis infection or mixed infection occurred in the 2,000 broilers, and the preventive protection rate reached 100%.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides a chicken IBH (inclusion body hepatitis) egg yolk antibody and an application of the chicken IBH egg yolk in preparation of a chicken IBH treatment drug. According to the technical scheme, the category of immunostimulation antigen is preferred to improve the immunotherapy effect, three viruses AV208, AV209 and AV211 are innovatively taken as antigen substances, a polyvalent vaccine is first prepared, and the antibody is generated through stimulation of the polyvalent vaccine. On the basis, in order to obtain better antibody titer, a specific mode and the antibody collection time are designed, a mild antibody purification means is adopted, and an obtained product has higher antibody titer. A curative effect verification test proves that although only three serotype adenovirus strains are taken as antigens, the obtained egg yolk antibody has a universal prevention and treatment effect on the chicken IBH because of the efficient preparation means and analytical investigation of antigen substances and pathopoiesis capability of the chicken IBH.

Description

technical field [0001] The invention relates to the technical field of veterinary biological products, in particular to an egg yolk antibody for chicken inclusion body hepatitis and its application for preparing medicines for treating chicken inclusion body hepatitis. Background technique [0002] Chicken inclusion body hepatitis (IBH) is an acute infectious disease caused by certain serotypes of avian adenovirus group I. The disease occurs mostly in broilers aged 3 to 6 weeks, and can also occasionally occur in laying hens or breeders within 20 weeks of age. There is no gender difference, and it rarely occurs in older broilers. Various strains of broiler chickens are susceptible to the disease, and other poultry such as turkeys, geese, and pheasants have also been reported. Clinically, it is characterized by sudden increase in mortality, anemia and hemorrhagic inclusion body hepatitis. The infection route of this disease is mainly the respiratory tract, digestive tract an...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C07K16/08C07K16/02A61K39/42A61P31/20
CPCC07K16/081A61K2039/505A61K2039/54A61K2039/545C07K16/02C07K2317/11
Inventor 张永欣苏建东杨保收付旭彬李守军
Owner TIANJIN RINGPU BIO TECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap